Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The CNSP news feed highlights the company’s announcements about its clinical programs, corporate developments, and interactions with the scientific and investment communities.
A central theme in CNS Pharmaceuticals’ news is the progress of its lead drug candidate, TPI 287. The company issues updates on clinical data, including Phase 1 results in glioblastoma patients treated with TPI 287 in combination with bevacizumab, and discusses the potential of TPI 287 to cross the blood-brain barrier and treat CNS tumors. Releases also describe the breadth of indications in which TPI 287 has been studied, from recurrent glioblastoma and pediatric neuroblastoma to metastatic melanoma and breast cancer metastatic to the brain.
News items also cover scientific visibility, such as acceptance of abstracts for poster presentation at the Society of Neuro-Oncology Annual Meeting. These abstracts, as described by the company, address topics like Berubicin in glioblastoma and pediatric diffuse midline glioma, as well as future evaluation of TPI 287 in CNS diseases. In addition, CNS Pharmaceuticals reports participation in investor conferences and virtual events, where management discusses its development strategy and corporate outlook.
Corporate and governance updates appear in the news as well, including announcements of a 1-for-12 reverse stock split and leadership changes, such as the planned transition of the chief executive officer role to Rami Levin. For investors and observers following CNSP, this news page provides a centralized view of the company’s disclosed milestones in neuro-oncology drug development, capital structure decisions, and executive leadership.
CNS Pharmaceuticals (NASDAQ: CNSP) is urging shareholders to vote in favor of two proposals at the upcoming Annual Shareholder Meeting on July 27, 2022. The proposals seek authorization to increase the number of shares available for issuance and allow the Board to conduct a reverse stock split at a ratio between 1-for-2 and 1-for-30. CEO John Climaco emphasized the necessity of these measures to secure financing and maintain the NASDAQ listing amidst challenging market conditions, while stressing that such actions will only be undertaken if truly needed.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced FDA approval for a protocol amendment to its global trial on Berubicin, targeting recurrent glioblastoma multiforme (GBM). The trial has expanded patient eligibility to those who have undergone multiple first-line therapies. With 19 clinical sites currently active and an additional 42 set to open in Europe and the U.S., the company aims to enhance patient access. A non-binding futility analysis will occur after 30-50% of subjects complete six months, without pausing enrollment. Berubicin, noted for crossing the blood-brain barrier, demonstrates potential in treating aggressive brain cancer.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) recently presented an overview of its ongoing clinical trial for Berubicin, aimed at treating recurrent glioblastoma multiforme (GBM), at the ASCO 2022 Annual Meeting. Berubicin, the first anthracycline to cross the blood-brain barrier, demonstrated greater cytotoxicity compared to doxorubicin in GBM cell lines. The ongoing global study involves 243 patients and assesses Berubicin's efficacy against Lomustine. Positive feedback from European regulatory authorities enhances confidence in the trial's design, which aims to address significant unmet medical needs in GBM treatment.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced CEO John Climaco's participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami. A video of the presentation will be available for on-demand viewing for registered attendees. CNS is focused on developing novel treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, which crosses the blood-brain barrier. The company is also advancing the WP1244 drug technology, showcasing promising preclinical results against various cancers.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that its abstract was accepted for presentation at the ASCO 2022 Annual Meeting, taking place from June 3-7, 2022 in Chicago, IL. The poster titled 'Design and initiation of an adaptive, randomized, controlled study of berubicin for recurrent glioblastoma multiforme' will be presented by Dr. Sandra L. Silberman on June 5, 2022. Berubicin is noted as the first anthracycline able to cross the blood-brain barrier and aims to treat aggressive brain cancers. This represents a significant milestone in CNSP's development of innovative cancer therapies.
CNS Pharmaceuticals (CNSP) announced financial results for Q1 2022, reporting a net loss of approximately $2.8 million, down from $3.6 million year-over-year. The company is expanding its Berubicin study in Switzerland, France, and Spain, aiming to enhance patient enrollment in the pivotal trial for glioblastoma multiforme (GBM). Berubicin has received Fast Track and Orphan Drug Designation from the FDA, potentially accelerating its development. CNSP also has cash on hand of around $12.4 million, expected to fund operations into Q1 2023.
CNS Pharmaceuticals (NASDAQ: CNSP) has received regulatory approval from Spain's AEMPS and the Sevilla Ethics Committee for its pivotal study of Berubicin, targeting recurrent glioblastoma multiforme (GBM). This trial aims to evaluate the efficacy and safety of Berubicin, which uniquely crosses the blood-brain barrier. Approximately 243 patients will be randomized to assess Overall Survival, a key FDA-endorsed endpoint. The study includes a planned futility analysis and has received Fast Track Designation from the FDA for expedited review.
JTC Team continues its Virtual Investor Spotlight Series on April 14, 2022, featuring presentations from Aeterna Zentaris (NASDAQ:AEZS), CNS Pharmaceuticals (NASDAQ:CNSP), and American Resources Corporation (NASDAQ:AREC). The series highlights Aeterna's pre-clinical pipeline addressing unmet medical needs, CNS's advancements in treating Glioblastoma, and discussions on national security regarding rare earth elements with American Resources. Live webcasts will be available, providing insights into these companies and their ongoing projects.
CNS Pharmaceuticals, a biopharmaceutical company focused on cancer treatments, will participate in a Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on April 14, 2022, at 11:30 AM ET. The event will feature CEO John Climaco and Key Opinion Leader Dr. Samuel A. Goldlust discussing CNS's innovative drug, Berubicin, aimed at treating recurrent GBM. Berubicin is the first anthracycline drug to potentially cross the blood-brain barrier, showcasing promising results in early trials for aggressive brain cancer.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has received the green light from the French ethics committee and the National Agency for the Safety of Medicines for its pivotal study of Berubicin, a treatment for recurrent glioblastoma multiforme (GBM). This approval opens doors to patient enrollment in France, a key step in advancing the trial. The study will involve 243 adults, with Overall Survival as the primary endpoint. Berubicin has also received Fast Track Designation and Orphan Drug Designation from the FDA, highlighting its potential as a groundbreaking therapy for GBM.